Symphogen

Baxalta, Symphogen ink immuno-oncology collaboration

Monday, January 4, 2016

Baxalta, a global biopharmaceutical provider dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Symphogen, a private biopharmaceutical company developing recombinant antibodies and antibody mixtures, have announced a broad, strategic immuno-oncology collaboration.

[Read More]